PBS (without Mg²⁺ and Ca²⁺) pH 7.4, 150mM NaCl, 0.02% sodium azide, 50% glycerol
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Peptide sequence around phosphorylation site of tyrosine 770 (T-E-Y(p)-M-T) derived from human CBL.
Purified by antigen-affinity chromatography. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Cbl proto-oncogene , C-CBL , CBL2 , FRA11B , NSLL , RNF55
Cytoplasm,Cell membrane,Golgi apparatus
This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Jul 2016]